πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 750 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9545442

Activatable antibodies that bind epidermal growth factor receptor and methods of use there

CytomX Therapeutics, Inc. Β· Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9546176

Small molecule bicyclic and tricyclic CFTR correctors

DISCOVERYBIOMED, INC. Β· Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9540440

Activatable antibodies that bind epidermal growth factor receptor and methods of use there

CytomX Therapeutics, Inc. Β· Granted Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9526777

Methods for the induction of ebola virus-specific immune responses comprising administerin

The United States of America, as represented by the Department of Health and Human Services Β· Granted Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9522955

Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of s

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9506926

Molecular predictors of therapeutic response to specific anti-cancer agents

The Regents of the University of California Β· Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9504762

Adeno-associated virus factor VIII vectors

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9492415

Methods of treating Parkinson's disease using viral vectors

The Regents of the University of California Β· Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9492430

Methods and compositions associated with the granulocyte colony-stimulating factor recepto

Ligand Pharmaceuticals Incorporated Β· Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9493757

Modified factor VII or factor VIIa polypeptides

Regents of the University of Minnesota Β· Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9493544

Von willebrand factor- and factor VIII-polymer conjugates having a releasable linkage

Nektar Therapeutics Β· Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9476037

Factor VII polypeptides that are modified and uses thereof

Catalyst Biosciences, Inc. Β· Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9468649

Methods of treating epilepsy with transforming growth factor beta inhibitors

The Regents of the University of California Β· Granted Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9447419

RNAi-mediated inhibition of tumor necrosis factor Ξ±-related conditions

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9439979

Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9441225

Compositions and methods for inhibiting expression of factor V

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9353178

Stem cell factor inhibitor

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9352027

Albumin-free factor VIII formulations

UNIVERSITY OF CONNECTICUT Β· Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9347054

Polymer factor IX moiety conjugates

Nektar Therapeutics Β· Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9328339

Modified factor IX polypeptides and uses thereof

Catalyst Biosciences, Inc. Β· Granted Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9309535

Combination anti-HIV vectors, targeting vectors, and methods of use

The Regents of the University of California Β· Granted Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9272023

Use of ixolaris, a tissue factor inhibitor, for inhibiting angiogenesis

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9266960

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of sa

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9254316

Adenoviral vector-based malaria vaccines

United States of America as represented by the Secretary of the Air Force Β· Granted Tue Feb 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted